Biosimilar Monoclonal Antibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Product (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab and Other), By Application (Oncology, Chronic & Autoimmune Diseases, Others), By Region, and Competition
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationBiosimilar Monoclonal Antibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028, Segmented By Product (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab and Other), By Application (Oncology, Chronic & Autoimmune Diseases, Others), By Region, and Competition
| Forecast Period | 2024-2028 |
| Market Size (2023) | USD 5.22 billion |
| CAGR (2023-2028) | 11.87% |
| Fastest Growing Segment | Oncology |
| Largest Market | Asia-Pacific |
Market Overview
Global Biosimilar Antibody Market stood at USD5.22 billion in 2022 and is anticipated to grow at a robust rate of 11.87% through 2028. The biosimilar monoclonal antibodies (mAbs) market has emerged as a dynamic and transformative sector within the biopharmaceutical industry. Biosimilars, often referred to as "generic" versions of biologic drugs, have gained significant attention for their potential to provide cost-effective alternatives to expensive biologics while maintaining comparable safety and efficacy profiles. In recent years, biosimilar mAbs have been making remarkable strides, reshaping the pharmaceutical landscape and opening doors to improved patient access and healthcare affordability. Monoclonal antibodies are a class of biologic drugs designed to target specific proteins, cells, or tissues within the body. They have proven to be highly effective in treating a wide range of diseases, including cancer, autoimmune disorders, and inflammatory conditions. However, the complex nature of mAbs and the intricate manufacturing processes involved have led to high development costs and subsequently elevated treatment expenses. Biosimilar mAbs, in essence, are highly similar versions of approved reference mAbs. They are developed using recombinant DNA technology and manufactured in living cells. While they may not be identical to the reference product due to inherent variability in biologics, they are designed to be as close as possible in terms of safety, efficacy, and quality. One of the primary drivers is the urgent need for cost containment within healthcare systems worldwide. Biosimilar mAbs offer the potential to reduce healthcare expenditure significantly, as they typically enter the market at a lower price point compared to their reference counterparts, hence augmenting the growth of the market in the projected period.
Key Market Drivers
Rising Cancer and Autoimmune Disorders Driving the Biosimilar Monoclonal Antibodies Market
In In recent years, the healthcare landscape has witnessed a significant surge in the prevalence of cancer and autoimmune disorders, two complex and challenging medical conditions that affect millions of individuals worldwide. As the incidence of these conditions continues to rise, the demand for effective and affordable treatments has led to the emergence and expansion of the biosimilar monoclonal antibodies (mAbs) market. This rapidly evolving market segment is playing a pivotal role in addressing the therapeutic needs of patients while offering potential cost savings for healthcare systems.
Rising Regulatory Support Driving the Biosimilar Monoclonal Antibodies Market
To address concerns about the safety, efficacy, and quality of biosimilar monoclonal antibodies, regulatory agencies around the world have developed comprehensive guidelines and frameworks. These guidelines outline the rigorous scientific and clinical evaluation processes that biosimilar products must undergo before they can be approved for market entry. The goal is to ensure that patients and healthcare professionals can trust the equivalence of biosimilars to their reference products. For example, the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have both released guidelines specifically addressing biosimilar monoclonal antibodies. These guidelines emphasize the importance of extensive comparative analytical studies, including physicochemical and functional characterization, as well as non-clinical and clinical studies to demonstrate equivalence to the reference product. As more patents for originator monoclonal antibodies expire, the market is ripe for biosimilar alternatives. This creates opportunities for manufacturers to enter the market and offer alternatives at competitive prices. The rigorous regulatory pathways and guidelines set by agencies like the EMA and FDA have instilled confidence in both healthcare professionals and patients regarding the safety and efficacy of biosimilar monoclonal antibodies.
Download Free Sample Report
Key Market Challenges
Manufacturing Complexity
The manufacturing process for biosimilar mAbs is intricate and involves living cells, which can result in product variability. Maintaining consistent quality and comparability to the reference product is a significant challenge.
Clinical Trials and Data Requirements
Generating clinical trial data that demonstrates similarity in safety and efficacy between a biosimilar and its reference mAb is essential for regulatory approval. Designing these trials and ensuring patient recruitment can be complex and resource-intensive.
Market Competition
Key Market Trends
Technological Advancements
The pharmaceutical industry has experienced a seismic shift in recent years, driven by remarkable advancements in biotechnology and innovative research methodologies. Among the significant breakthroughs, biosimilar monoclonal antibodies (mAbs) have emerged as a potent force shaping the medical landscape. These cutting-edge therapeutic agents are revolutionizing the treatment of various diseases, ranging from cancer to autoimmune disorders. The rapid growth of the biosimilar mAbs market is intricately intertwined with the continual progress in technology and innovation. Advancements in technology have enabled a deeper understanding of disease mechanisms and patient variability. This has paved the way for the concept of precision medicine, where treatments are tailored to individual patients based on their genetic makeup, disease characteristics, and response to therapy. Biosimilar mAbs hold immense promise in this regard, as they can be developed to target specific disease pathways with greater precision. This approach not only enhances therapeutic outcomes but also minimizes side effects, thereby improving patient quality of life. One of the key drivers behind the biosimilar mAbs market's growth is the continual evolution of bioprocessing and manufacturing technologies. Innovations in cell culture techniques, purification processes, and bioreactor designs have enabled manufacturers to produce biosimilar mAbs with higher purity and yield. This not only ensures the safety of the end product but also reduces production costs, making these therapies more economically viable for patients and healthcare systems. Accurate characterization and comparison of biosimilar mAbs with their reference products are critical to ensuring their safety and efficacy. Technological advancements in analytical techniques, such as mass spectrometry, nuclear magnetic resonance, and high-performance liquid chromatography, have made it possible to comprehensively assess the structural and functional similarities between biosimilars and reference mAbs. This level of detail is essential for regulatory approval and gaining physicians' and patients' trust in the product.
Segmental Insights
Product Insights
In 2022, the Biosimilar Monoclonal Antibodies market was dominated by Infliximab segment and is predicted to continue expanding over the coming years.
Application Insights
In 2022, the Biosimilar Monoclonal Antibodies market was dominated by the Oncology segment and is predicted to continue expanding over the coming years.
Download Free Sample Report
Regional Insights
The Asia-Pacific region is home to a diverse range of economies, each with its unique healthcare challenges. As the burden of chronic diseases and complex medical conditions increases, the demand for effective and affordable treatment options has grown. Biosimilar monoclonal antibodies offer a viable solution, providing access to advanced therapies that were previously financially out of reach for many patients. With a focus on cost-effectiveness, Asian healthcare systems are increasingly turning to biosimilars to bridge the gap between patient needs and budget constraints.
Recent Developments
- In May 2023, Enzene Biosciences introduced Cetuximab, the inaugural biosimilar for cancer treatment. Marketed as Erbitux, Cetuximab is a chimeric monoclonal antibody with therapeutic applications. It serves as a focused treatment for metastatic colorectal cancer (mCRC) and head and neck cancer. The cost for an individual patient's eight-week treatment period is approximately $30,000.
- In July 2023, Aurobindo Pharma has notified the stock exchanges that its fully owned affiliate, CuraTeQ Biologics Private Ltd, has established an exclusive licensing arrangement with BioFactura Inc, a US company, to market BFI-751. This is a potential biosimilar of BioFactura's product Stelara (Ustekinumab).
Key Market Players
o
o
o
o
o
o
o
o
o
o
| By Product | By Application | By Region |
| • Infliximab • Rituximab • Abciximab • Trastuzumab • Adalimumab • Bevacizumab • Other | • Oncology • Chronic & Autoimmune Diseases • Others | • North America • Asia-Pacific • Europe • Middle East & Africa • South America |
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy